Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the…

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 4 news outlets

guideline: 1 clinical guideline source

Readers on

mendeley: 12 Mendeley

So far, Altmetric has seen 6 news stories from 4 outlets.

Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma

Pharmacy Times, 21 Apr 2024

Précis Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity…

Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

Cancer Network, 23 Nov 2023

Sagar Lonial, MD, FACP Emory University School of Medicine Cesar Rodriguez, MD Mount Sinai Hospital in New York City Luciano…

Novel Agents Highlight Changes in Myeloma Field

OncLive, 11 Jul 2023

Elizabeth “Betsy” O’Donnell, MD Therapeutic options for the treatment of patients with multiple myeloma (MM) are growing across…

Elranatamab Induces Responses in Patients With Relapsed/Refractory Multiple Myeloma Following BCMA-Directed Therapy

Oncology Nursing News, 15 Jun 2023

A pooled analyses of the phase 1 MagnetisMM-1 (NCT03269136), phase 1 MagnetisMM-2 (NCT04798586), phase 2 MagnetisMM-3 (NCT0464935…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.